Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients
Preprint
en Inglés
| medRxiv
| ID: ppmedrxiv-20038067
ABSTRACT
BackgroundDuring the coronavirus disease 2019 (COVID) pandemic, various organisations have produced management guidance for cancer patients and the delivery of cytotoxic chemotherapy, but none offer estimates of risk, or the potential impact across populations. MethodsWe combine data from four countries to produce pooled age-banded Case Fatality Rates (CFRs), calculate the sex-difference in survival and use data from four recent studies to convert CFRs into age-sex stratified Infection Fatality Rates (IFRs). We estimate the additional risk of death in cancer patients, and in those receiving chemotherapy. We illustrate the impact of these by considering the impact on a national incident cancer cohort and present some clinical scenarios. ResultsWe obtained data based on 412,985 cases and 41,854 deaths. The pooled estimate for IFR was 0.92%. Age-related IFRs for patients with cancer range from 0.01% to 29%, and higher in patients receiving chemotherapy. The risk is significantly higher in men than women. 40% of all male and 32% of all female patients with a new diagnosis of cancer this year have an IFR of [≥] 5%. ConclusionsOlder male patients are at a higher risk of death with COVID infection. Patients with cancer are also at higher risk, as are those who have recently received chemotherapy. We provide well-founded estimates to allow patients and clinicians to better balance these risks, and illustrate the wider impact in a national incident cohort. FUNDING & DISCLOSURESMW receives funding from the Imperial/ NIHR BRC; SD receives funding from the IC/ICR CRUK Major Centre; LPS receives funding from Brain Tumour Research and the Brain Tumour Research Campaign. JC is supported by the Guangdong International Young Research Talents Training Programme for Postdoctoral Researchers. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Code, data and appendicies are available at https//gitlab.com/computational.oncology/covidcancerrisk HIGHLIGHTSO_LIWe report case and infection fatality rates based on a large multi-national cohort C_LIO_LIWe provide sex and age-specific estimates of risk C_LIO_LIWe provide estimates of additional risk for patients with cancer to allow patients and clinicians to balance risk and benefit C_LI
cc_by_nc_nd
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
medRxiv
Tipo de estudio:
Cohort_studies
/
Estudio observacional
/
Estudio pronóstico
Idioma:
Inglés
Año:
2020
Tipo del documento:
Preprint